Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Trends Parasitol. 2010 Mar;26(3):145-51. doi: 10.1016/j.pt.2009.12.005. Epub 2010 Feb 3.

Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination.

Author information

  • 1Medicines for Malaria Venture, Geneva, Switzerland. wellst@mmv.org

Abstract

Plasmodium vivax is the major species of malaria parasite outside Africa. It is especially problematic in that the infection can relapse in the absence of mosquitoes by activation of dormant hypnozoites in the liver. Medicines that target the erythrocytic stages of Plasmodium falciparum are also active against P. vivax, except where these have been compromised by resistance. However, the only clinical therapy against relapse of vivax malaria is the 8-aminoquinoline, primaquine. This molecule has the drawback of causing haemolysis in genetically sensitive patients and requires 14 days of treatment. New, safer and more-easily administered drugs are urgently needed, and this is a crucial gap in the broader malaria-elimination agenda. New developments in cell biology are starting to open ways to the next generation of drugs against hypnozoites. This search is urgent, given the time needed to develop a new medication.

Copyright 2010 Elsevier Ltd. All rights reserved.

PMID:
20133198
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Write to the Help Desk